Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Acquired by Mackenzie Financial Corp

Mackenzie Financial Corp lifted its stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 499.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 299,815 shares of the company's stock after acquiring an additional 249,765 shares during the quarter. Mackenzie Financial Corp owned 0.13% of Gossamer Bio worth $271,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Graham Capital Management L.P. acquired a new position in Gossamer Bio during the 4th quarter worth $32,000. Fullcircle Wealth LLC purchased a new position in shares of Gossamer Bio in the 4th quarter valued at about $43,000. Velan Capital Investment Management LP purchased a new position in shares of Gossamer Bio in the 4th quarter valued at about $68,000. Bank of America Corp DE grew its position in shares of Gossamer Bio by 107.2% during the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company's stock worth $77,000 after buying an additional 43,866 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Gossamer Bio during the fourth quarter worth about $90,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Stock Up 5.6%

Shares of NASDAQ GOSS traded up $0.07 during midday trading on Friday, hitting $1.33. 1,427,482 shares of the company's stock were exchanged, compared to its average volume of 1,556,752. The firm's fifty day simple moving average is $1.02 and its 200-day simple moving average is $1.03. The company has a market cap of $302.31 million, a PE ratio of -4.16 and a beta of 1.85. Gossamer Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.55. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $9.89 million during the quarter, compared to analysts' expectations of $3.95 million. Research analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on GOSS. Wedbush reaffirmed an "outperform" rating and issued a $4.00 target price on shares of Gossamer Bio in a report on Friday, May 16th. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Tuesday, March 18th. Finally, The Goldman Sachs Group lifted their price objective on shares of Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, May 16th.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.